This company has been acquired
Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Alimera Sciences Temettü
Temettü kriter kontrolleri 0/6
Alimera Sciences does not have a record of paying a dividend.
Anahtar bilgiler
n/a
Temettü verimi
n/a
Ödeme oranı
Sektör ortalama getirisi | 2.2% |
Bir sonraki temettü ödeme tarihi | n/a |
Eski temettü tarihi | n/a |
Hisse başına temettü | n/a |
Hisse başına kazanç | -US$0.28 |
Temettü verim tahmini | n/a |
Son temettü güncellemeleri
Güncelleme yok
Recent updates
Alimera Sciences: Deal Closing After All, CVR Still Attractive
Sep 11Alimera Sciences: Cheap CVR Optionality
Jul 16Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)
Jun 18Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story
Feb 15Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?
Dec 30Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)
Oct 13Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?
Sep 13Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data
Oct 06Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland
Sep 20Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection
Aug 09Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection
Jul 22Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation
Jul 08Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?
Mar 24Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?
Nov 06Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem
Aug 24Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares
Feb 11Alimera Sciences (ALIM) Investor Presentation - Slideshow
Nov 18Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: Insufficient data to determine if ALIM's dividends per share have been stable in the past.
Büyüyen Temettü: Insufficient data to determine if ALIM's dividend payments have been increasing.
Piyasaya Karşı Temettü Getirisi
Alimera Sciences Piyasaya Karşı Temettü Getirisi |
---|
Segment | Temettü Verimi |
---|---|
Şirket (ALIM) | n/a |
Pazarın Alt %25'i (US) | 1.4% |
Pazarın En İyi %25'i (US) | 4.4% |
Sektör Ortalaması (Pharmaceuticals) | 2.2% |
Analist tahmini (ALIM) (3 yıla kadar) | n/a |
Önemli Temettü: Unable to evaluate ALIM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Yüksek Temettü: Unable to evaluate ALIM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: Insufficient data to calculate ALIM's payout ratio to determine if its dividend payments are covered by earnings.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as ALIM has not reported any payouts.